Hikma introduces Respirox to the Tunisian market

February 2010, Hikma Pharmaceuticals introduces Respirox; the Atypical antipsychotic, to Tunisian market. The active ingredient Risperidone is one of the leading antipsychotics and has major role in the treatment of schizophrenia, bipolar disorder and agitation associated with autism.

Press Release Product 3 March 2010

Important notice for users

You are about to access Hikma historic archive material. Any reference in these archives to Hikma products or their uses may not reflect current medical knowledge and should not be used as a source of information on the present product label, efficacy data, or safety data. Please refer to your approved national product label (SmPC) for current product information.

I have read this warning and will not be using any of the contained product information for clinical purposes.